Trials / Terminated
TerminatedNCT03848832
Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- All
- Age
- 2 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing symptom severity when compared with placebo, in participants with Rett syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GWP42003-P | GWP42003-P presented as an oral solution containing cannabidiol |
| DRUG | Placebo | Matching placebo oral solution |
Timeline
- Start date
- 2019-07-29
- Primary completion
- 2021-01-21
- Completion
- 2021-01-21
- First posted
- 2019-02-21
- Last updated
- 2022-09-02
- Results posted
- 2021-12-29
Locations
26 sites across 4 countries: United States, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03848832. Inclusion in this directory is not an endorsement.